Home›Research›Compare›Liraglutide vs Tirzepatide
Peptide ComparisonLiraglutide vs Tirzepatide
Both are Metabolic peptides.
Liraglutide
Victoza
Half-life: 13 hours
52 providers listed
Tirzepatide
Dual GLP-1
Half-life: ~5 days (once-weekly dosing)
541 providers listed
Tirzepatide has a longer half-life than Liraglutide, so it generally needs less frequent dosing.
Liraglutide
Half-life
13 hours
Tirzepatide
Half-life
~5 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Less frequent dosing (longer half-life) | Tirzepatide |
| More provider options (52 vs 541) | Tirzepatide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Liraglutide
Tirzepatide
Liraglutide
Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measur…
Semaglutide vs liraglutide for weight loss in adults with overweight or obesity
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.
+4 more
Tirzepatide
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospectiv…
+5 more
About Liraglutide
GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion
About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Liraglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Tirzepatide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Where to source these peptides
Liraglutide
52 listed
Browse directory →
Providers offeringTirzepatide
541 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.